Armando Orlandi· @ArmandOrlandi · X·· 2 天前评分70
正文 · 原文
Cowabunga! 🌊 Riding the Metastatic Breast Cancer Wave 🏄🏻♂️🤙🏻 from #ESMO26
HORIZON-Breast06: trastuzumab rezetecan vs chemo in HER2-low disease.
Progression-free survival 16.4 vs 6.8 mo, hazard ratio 0.27.
HER2-low is ADC territory now. Which antibody-drug conjugate, and when?
@OncoAlert @Larvol
126 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
LBA13按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.org来源：Armando Orlandi · x.com